About Elutia Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of ...
Vaxart reported a net loss of $14.1 million for the third quarter of 2024, compared to $17.4 million for the third quarter of 2023. Net loss per share for the third quarter of 2024 was $0.06, compared ...